Introduction {#s1}
============

Invasive amebiasis (IA) caused by *Entamoeba histolytica* is the second most common cause of mortality associated with parasitic infections worldwide, accounting for 40,000 to 100,000 deaths annually [@pntd.0001318-Walsh1]. Amebiasis is transmitted by ingestion of food or water containing the cyst form of *E. histolytica*, which is prevalent in developing countries in Central and South America, Asia, and Africa. In the developed countries, most cases arise in travelers and immigrants from such endemic areas [@pntd.0001318-Haque1]. Recently, however, three developed East Asian countries (Japan, Taiwan, and South Korea) reported increased risk for amebiasis among men who have sex with men (MSM) due to oral-anal sexual contact [@pntd.0001318-Takeuchi1]--[@pntd.0001318-Hung3]. The annual incidence of human immunodeficiency virus type 1 (HIV-1) infection is also increasing among MSM in these countries [@pntd.0001318-Chen1]-[@pntd.0001318-Tsai1], resulting in growing concern on IA in HIV-1-infected MSM [@pntd.0001318-Ohnishi1], [@pntd.0001318-Park1]--[@pntd.0001318-Hung3], [@pntd.0001318-Powell1]. The recommended treatment for IA is metronidazole (750 mg t. i. d. for 10 days) or tinidazole (2 g q. d. for 3 days), followed by a luminal agent (paromomycin 500 mg t. i. d. for 10 days or diloxanide furoate 500 mg t. i. d. for 10 days) to eliminate intestinal colonization [@pntd.0001318-Powell1], [@pntd.0001318-Powell2]. A previous report described no difference in the response to metronidazole or tinidazole treatment between HIV-1-positive and --negative IA patients [@pntd.0001318-Hsu1]. However, the efficacy of luminal treatment in preventing recurrence, which can arise by relapse or re-infection, has not yet been assessed rigorously. In this study, we retrospectively analyzed 170 HIV-1-infected Japanese patients with IA, together with genomic typing of *E. histolytica* in 14 of these patients, and delineated the clinical features of IA in HIV-1-infected individuals and the efficacy of metronidazole, tinidazole and luminal treatment.

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

The Institutional Review Board of National Center for Global Health and Medicine (Tokyo, Japan) approved this study. All patients who provided clinical samples for genotyping of *E. histolytica* gave written informed consent.

Case review {#s2b}
-----------

The medical records of HIV-1-infected cases diagnosed with IA at the AIDS Clinical Center, National Center for Global Health and Medicine, between April 1997 and March 2010, were reviewed. The diagnosis of IA was made when one of the following criteria was satisfied; 1) identification of and/or positive PCR (methods; see below) in clinical specimens (stool or punctuate-exudate) for erythrophagocytic trophozoites in patients with IA-related symptoms, e.g., fever and liver abscess, or tenesmus and diarrhea, 2) high serum titer (\>1∶100) for antibody against *E. histolytica* in patients with IA-related symptoms in whom microbiological cultures or histological examination of clinical specimens did not identify any pathogen, and who showed improvement of IA symptoms following metronidazole or tinidazole monotherapy [@pntd.0001318-Hung1]--[@pntd.0001318-Hung3]. The medical records were surveyed for patients\' characteristics, presenting forms of clinical IA \[e.g., colitis, amebic liver abscess (ALA), and perianal abscess\], HIV-1-induced immunocompromised status, and symptoms, laboratory data and serological markers of other sexually-transmitted diseases (STD) including syphilis, hepatitis B and C viruses (HBV and HCV). After completion of treatment for IA, the medical records were followed-up until March 2010, excluding those cases found to have died or lost to follow-up.

Genotyping of *E. histolytica* {#s2c}
------------------------------

To determine the strains of *E. histolytica* among HIV-1-infected Japanese patients, genotyping of *E. histolytica* was performed in patients who were PCR positive. The PCR method was used for the first time in our clinic for the diagnosis of amebiasis in December 2008, and since then 14 patients had been diagnosed as IA based on a positive PCR. For the PCR, DNAs were extracted from various biological specimens (e.g., stool, colon wash and punctuate-exudate) by using QIAamp DNA stool Mini Kit (Qiagen, Valencia, CA). Polymerase chain reactions were performed with specific sets of primers designed to target each of 6 loci (D-A, S-Q, R-R, A-L, S^TGA^-D, and N-K) of tRNA-linked polymorphic short tandem repeats (STR), as described previously [@pntd.0001318-Ali1]. The PCR product was sequenced by ABI 3130XL Genetic Analyzer (Applied Biosystem, Foster city, CA) in both forward and reverse directions. Phylogenetic analysis and genotyping were performed as described previously [@pntd.0001318-EscuetadeCadiz1].

Statistical analysis {#s2d}
--------------------

Differences in patients\' characteristics and clinical features were examined using the chi-square test or nonparametric test. The cumulative risk for recurrence was analyzed by the Kaplan-Meier method, and differences were tested by the log-rank test. The Cox proportional hazards model was used to assess the impact of luminal treatment on the recurrence rate after adjustment for other factors. The hazard ratio and 95% confidence interval were calculated. *P* values less than 0.05 were considered to denote statistical significance. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL).

Results {#s3}
=======

Clinical data and response to treatment {#s3a}
---------------------------------------

IA was diagnosed in 170 HIV-1-infected cases between April 1997 and March 2010 (including amebic colitis, n = 102; ALA, n = 63; and perianal abscess, n = 5, [Table 1](#pntd-0001318-t001){ref-type="table"}). Thirty-three patients had two of the above three clinical forms of IA. All patients were males and 164/170 (96.5%) were MSM. High rates of positive TPHA (*Treponema pallidum* hemagglutination assay) (71.2%) and HBV exposure (HBs antigen-positive, HBs antibody-positive, or HBc antibody-positive) (60.0%) were observed. No significant differences were seen in CD4 counts, HIV-1 loads, coexisting AIDS definite disease and the proportion of patients treated with antiretrovirals, suggesting that HIV-induced immunocompromised status did not have an impact on the clinical presentation of amebic infection, in agreement with previous data [@pntd.0001318-Hung3]. In cases of amebic colitis (n = 102), diarrhea (69.7%) was the most common symptom followed by dysentery (55.9%) ([Table 2](#pntd-0001318-t002){ref-type="table"}). Fever (\>37.5°C) was seen in only 20 patients (19.6%), including 5 cases with perforative peritonitis. In cases with ALA (n = 63), fever (95.2%) was the most common symptom followed by abdominal pain (55.6%). Diarrhea (46.0%) and dysentery (19.0%) were only seen in less than half of ALA cases. Single abscess (72.6%) was identified in most cases. Liver abscesses were seen more frequently in the right lobe (70.5%) than the left (9.8%). Nine patients (14.3%) had pleuritis (considered a co-existing disease), as well as abscesses in the right lobe, and 7 of these presented chest pain. Comparison of physical and laboratory data showed higher peak body temperature (BT), leukocyte count and C reactive protein (CRP) in ALA cases ([Table 2](#pntd-0001318-t002){ref-type="table"}) and perforative peritonitis cases (data not shown) compared with colitis cases, indicating that high fever, leukocytosis and high CRP could be the signs of extraluminal amebiasis. It is reported that high fever and leukocytosis are also common in ALA patients free of HIV-1 infection, though both parameters were unusually associated with simple amebic colitis [@pntd.0001318-Stanley1]. In ALA cases, however, leukocyte count correlated positively with CD4 count (data not shown in tables: Pearson product-moment correlation coefficient 0.36, *p* value 0.004) and negatively with HIV-RNA load (Pearson product-moment correlation coefficient -0.28, *p* value 0.03), but CRP correlated neither with CD4 count nor HIV-RNA load (CRP-CD4, *p* = 0.81, CRP-HIV-RNA, *p* = 0.32). There were also no correlations between CD4 count, HIV-RNA load, BT, leukocyte count or CRP and abscess size or number.

10.1371/journal.pntd.0001318.t001

###### Patient demographics, state of HIV, and serological markers.

![](pntd.0001318.t001){#pntd-0001318-t001-1}

                                   Colitis (n = 102)[1](#nt102){ref-type="table-fn"}   ALA (n = 63)[2](#nt103){ref-type="table-fn"}   Perianal abscess (n = 5)[3](#nt104){ref-type="table-fn"}      All (n = 170)      *P* value[4](#nt105){ref-type="table-fn"}
  ------------------------------- --------------------------------------------------- ---------------------------------------------- ---------------------------------------------------------- --------------------- -------------------------------------------
  Age (years) \[IQR\]                                38 \[32--43\]                                    37 \[31--44\]                                              45                                 38 \[31--44\]                        0.58
  Male sex (%)                                         102 (100)                                         63 (100)                                             5 (100)                                 170 (100)                           --
  Homosexual (%)                                       96 (94.1)                                         63 (100)                                             5 (100)                                164 (96.5)                          0.053
  Past History of amebiasis (%)                        16 (15.7)                                         9 (14.3)                                             1 (20.0)                                26 (15.3)                          0.81
  CD4 count (/µl)                                   262 \[98--398\]                                  271 \[123--411\]                                            58                               269 \[107--403\]                       0.84
  HIV-RNA (log copies/ml)                         4.60 \[3.89--5.32\]                              4.66 \[3.91--5.11\]                                          5.04                             4.66 \[3.93--5.28\]                     0.70
  AIDS (%)                                             18 (17.6)                                         8 (12.7)                                             2 (40.0)                                28 (16.5)                          0.40
  ART initiated (%)                                    18 (17.6)                                        11 (17.5)                                             1 (20.0)                                30 (17.6)                          0.98
  TPHA test positive (%)                               77 (75.5)                                        40 (63.5)                                             4 (80.0)                               121 (71.2)                          0.10
  HBV exposure (%)                                     59 (57.8)                                        41 (65.1)                                             2 (40.0)                               102 (60.0)                          0.36
  HCV Antibody positive (%)                             3 (2.9)                                          3 (4.8)                                               0 (0)                                   6 (3.5)                           0.42

Data are median \[interquartile range: IQR\] or number (percentage) of patients.

5 cases of perforative peritonitis are included as co-existing diseases. Four cases were diagnosed coincidentally by colonoscopy in asymptomatic patients.

31 cases of colitis, 1 case of perianal abscess, 9 cases of pleuritis, and 2 cases of peritonitis are included as co-existing diseases.

1 case of colitis is included as co-existing diseases.

Chi-square test or non-parametric test was performed for data of colitis and ALA.

UD: undetectable, ART: anti-retroviral therapy, TPHA test: *Treponema pallidum* Hemagglutination Assay test, HBV exposure: HBsAg-positive or HBsAb-positive, and/or HBc-Ab positive.

10.1371/journal.pntd.0001318.t002

###### Clinical features of amoebic colitis and ALA.

![](pntd.0001318.t002){#pntd-0001318-t002-2}

                                                            Colitis (n = 102)          ALA (n = 63)        *P* value
  ------------------------------------------------------- ---------------------- ------------------------ -----------
  Symptoms                                                                                                
  Diarrhea (%)                                                71/102 (69.6)            29/63 (46.0)          0.003
  Dysentery (%)                                               57/102 (55.9)            12/63 (19.0)         \<0.001
  Abdominal pain (%)                                          23/102 (22.5)            35/63 (55.6)         \<0.001
  Chest pain (%)                                               0/102 (0.0)             7/63 (11.1)          \<0.001
  Peak BT (°C) \[IQR\][3](#nt109){ref-type="table-fn"}     36.8 \[36.5--37.4\]     39.0 \[38.8--39.5\]      \<0.001
  WBC (/µ l) \[IQR\][3](#nt109){ref-type="table-fn"}       5,830 \[4490--7580\]   11,760 \[9460--15170\]    \<0.001
  CRP (mg/dl) \[IQR\][3](#nt109){ref-type="table-fn"}      0.62 \[0.16--3.02\]    19.15 \[10.53--24.75\]    \<0.001
  Frequency of diarrhea[1](#nt107){ref-type="table-fn"}                                                   
  ≤ 5 times/day (%)                                           63/101 (62.4)                 --            
  6--10 times (%)                                             26/101 (25.7)                 --            
  ≥ 11 times (%)                                              12/101 (11.9)                 --            
  Size of abscess (mm)                                              --                 59 (10--180)       
  Location of abscess[2](#nt108){ref-type="table-fn"}                                                     
  Right lobe only                                                   --                 43/61 (70.5)       
  Left lobe only                                                    --                  6/61 (9.8)        
  Both lobes                                                        --                 12/61 (19.7)       
  Number of abscesses[1](#nt107){ref-type="table-fn"}                                                     
  Single (%)                                                        --                 45/62 (72.6)       
  Multiple (%)                                                      --                 17/62 (27.4)       

Data of one case were not available.

Data of two cases were not available.

Data are median \[interquartile range: IQR\] or number (percentage) of patients. BT: body temperature, WBC: White Blood Cell counts, CRP: C reactive protein.

All patients were treated with metronidazole (750 mg t. i. d. for 10 days) for IA, with the exception of two who were treated with tinidazole (2 g q. d. for 3 days). Complete remission of all IA symptoms was observed in 165 patients including the two treated with tinidazole. Five cases died within six months after diagnosis of IA; two from complications related to amebic colitis (one peritoneal perforation and one gastrointestinal bleeding), one from malignant lymphoma, one from *Pneumocystis jirovecii* pneumonia, and one from pulmonary thrombosis. The overall mortality rate was 3% in this study, which was comparable to those reported in non-HIV cases [@pntd.0001318-Haque1], [@pntd.0001318-Stanley1].

Recurrence after treatment {#s3b}
--------------------------

Luminal agents; paromomycin and diloxanide, are not approved in Japan, and they were not always available in our facility during the study period. After completion of IA treatment with metronidazole or tinidazole, luminal agents were administered when available. Consequently, 83 cases were treated with luminal agents; 38 cases with promomycin (500 mg t. i. d. for 10 days) and 45 cases with diloxanide furoate (500 mg t. i. d. for 10 days). No significant differences were seen in patients\' characteristics, including HIV-1-induced immunocompromised status, serological markers of other STD, and clinical forms and severity of amebiasis between the 83 cases with luminal treatment and 82 cases who did not receive such treatment ([Table S1](#pntd.0001318.s001){ref-type="supplementary-material"}). The median follow-up period after completion of metronidazole or tinidazole treatment was 50 months (inter quartile range: 19--85) in those who received luminal treatment, and 43 months (inter quartile range: 23--98) in those without.

Within the 12-month post-metronidazole treatment period, recurrence of IA was noted in only two patients who did not receive luminal treatment, suggesting reactivation of residual cysts of *E. histolytica* ([Figure 1](#pntd-0001318-g001){ref-type="fig"}). However, during the entire follow-up period, six in each group experienced recurrence of IA, with no significant difference in the recurrence frequency by the log-rank chi-square test. Multivariate analysis showed that recurrence did not correlate with past history of IA, CD4 count, TPHA, HBV exposure (HBs antigen-positive or HBs antibody-positive), or the presence of extraluminal IA disease ([Table 3](#pntd-0001318-t003){ref-type="table"}). However, a positive HCV antibody was significantly associated with IA recurrence. Recurrence also tended to occur in those who acquired new syphilis infection during the follow-up period, though the difference did not reach statistical significance.

![Kaplan-Meier estimates of time to IA recurrence.\
Cumulative probability of IA recurrence after completion of metronidazole or tinidazole treatment with or without subsequent luminal treatment.](pntd.0001318.g001){#pntd-0001318-g001}

10.1371/journal.pntd.0001318.t003

###### Multivariate analyses for factors associated with frequency of recurrence.

![](pntd.0001318.t003){#pntd-0001318-t003-3}

                                                               No recurrence (n = 153)[1](#nt110){ref-type="table-fn"}   Recurrence (n = 12)   Hazard ratio (95.0% CI)   *P v*alue
  ----------------------------------------------------------- --------------------------------------------------------- --------------------- ------------------------- -----------
  Past history of IA[2](#nt111){ref-type="table-fn"} (%)                              24 (15.7)                               2 (16.7)          0.914 (0.186--4.478)       0.911
  CD4 counts \<200[2](#nt111){ref-type="table-fn"} (%)                                57 (37.3)                               3 (25.0)          0.385 (0.101--1.470)       0.162
  TPHA test positive[2](#nt111){ref-type="table-fn"} (%)                             108 (70.6)                               10 (83.3)         2.435 (0.501--11.827)      0.270
  HBV exposure[2](#nt111){ref-type="table-fn"} (%)                                    92 (60.1)                               7 (58.3)          1.248 (0.364--4.277)       0.725
  HCV Antibody positive[2](#nt111){ref-type="table-fn"} (%)                            3 (2.0)                                2 (16.7)          7.664 (1.369--42.890)      0.020
  Extraluminal disease[2](#nt111){ref-type="table-fn"} (%)                            66 (43.1)                               4 (33.3)          0.559 (0.163--1.921)       0.356
  No luminal agent (%)                                                                76 (49.7)                               6 (50.0)          1.070 (0.322--3.559)       0.912
  Syphilis during follow-up period (%)                                                33 (21.6)                               7 (58.3)          3.332 (0.961--11.547)      0.059

Five patients died within 6 months from disease onset and their data were excluded from analysis.

Status at diagnosis of IA.

Genotypes of *E. histolytica* {#s3c}
-----------------------------

Genotyping of *E. histolytica* was performed in samples obtained from 14 patients between December 2009 and March 2010 (colitis, n = 8; ALA, n = 4; colitis and ALA, n = 1; and perianal abscess, n = 1; [Table S2](#pntd.0001318.s002){ref-type="supplementary-material"}). Eleven different genotypes were recognized, including five genotypes (J8, J12, J13, J20, and J23) identified previously in Japan [@pntd.0001318-EscuetadeCadiz1], and six newly recognized genotypes (J24-J29). There was no significant relation between *E. histolytica* genotype and clinical presentation.

Discussion {#s4}
==========

In the present study, retrospective analysis of the medical records of 170 patients with HIV-1-infection and IA showed no impact for HIV-1-induced immunocompromised status on the clinical forms of amebiasis. The physical and laboratory findings showed that high fever, leukocytosis and high CRP correlated with extraluminal diseases of amebiasis. In ALA cases, however, leukocyte count correlated positively with CD4 count and negatively with HIV-RNA load, indicating that CRP is more sensitive marker for the detection of the extraluminal diseases in advanced immunocompromised patients.

Only five patients died after the diagnosis of IA; two from IA complications and three from other causes. The results indicate excellent outcome for HIV-1-infected individuals with uncomplicated amebiasis treated with metronidazole or tinidazole, in agreement with previous reports on HIV and non-HIV cases [@pntd.0001318-Haque1], [@pntd.0001318-Hung2], [@pntd.0001318-Hung3], [@pntd.0001318-Hsu1], [@pntd.0001318-Stanley1]. Based on conventional wisdom and written opinion, adequate management of IA should include treatment with a luminal agent following metronidazole or tinidazole treatment, in order to eradicate residual cysts of *E. histolytica* due to the high rate (40--60%) of luminal colonization [@pntd.0001318-Haque1], [@pntd.0001318-Stanley1]--[@pntd.0001318-McAuley2]. On the other hand, the results of longitudinal observational studies indicated that asymptomatic cyst carriers rarely develop IA, and that cyst form ameba often disappears spontaneously without any treatment [@pntd.0001318-RuizPalacios1], [@pntd.0001318-Blessmann2]. There is controversy about the need for cyst eradication following metronidazole or tinidazole treatment, especially in endemic areas where re-infection is frequent. In this study, recurrence of IA within the first year of metronidazole treatment was noted in only two patients of 82 patients who did not receive luminal therapy. Moreover, long-term follow-up indicated IA recurrence also in those who received luminal agents, and the benefits obtained from luminal treatment seemed to have disappeared. IA recurred more frequently in those with HCV infection, which was recently reported to be transmittable sexually among MSM [@pntd.0001318-vandeLaar1], and in those who acquired new syphilis infection during the follow-up period, suggesting that sexually active MSM tend to experience IA recurrence due to re-acquisition of new *E. histolytica* infection. HBV exposure and positive TPHA at IA diagnosis did not correlate with IA recurrence probably because the high prevalence of these two parameters in this study masked the difference between recurrence and non-recurrence cases. Educational approach for safer sex may be more appropriate rather than luminal treatment to prevent IA recurrence after treatment.

Eleven genetic strains of *E. histolytica* were identified in this study and none of them had been reported so far from geographic areas other than Japan [@pntd.0001318-Ali1], [@pntd.0001318-EscuetadeCadiz1], [@pntd.0001318-Tawari1], [@pntd.0001318-Ali2], indicating that diverse Japan-specific isolates of *E. histolytica* are already prevalent among MSM in Japan. In fact, the *E. histolytica* seropositivity rate in HIV-1-infected MSM in our clinic was as high as 17.9% in 2009 (unpublished data), which is comparable with the seropositivity rate in Japanese MSM reported more than 20 years ago [@pntd.0001318-Takeuchi3]. Unfortunately, we could not compare the genotypes of *E. histolytica* between the incidences of the primary and recurrent IA within the same individuals due to the lack of appropriate stocked samples, which would have probably demonstrated acquisition of new infection.

Considered together, the results emphasize the difficulty of preventing IA recurrence without educational approach to prevent new amebic infection even after successful IA treatment in the high risk groups such as HIV-1-infected MSM. The spread of *E. histolytica* in MSM of other developed countries beyond Asia should be of great concern.
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